medigraphic.com
ISSN 1561-302X (Print)

2021, Number 2

<< Back Next >>

Rev cubana med 2021; 60 (2)

Clinical and immunological characteristics and organ damage in patients with idiopathic inflammatory myopathies

Arguelles ZAC, Chico CA, Kokuina E, Casas FN

Language: Spanish
References: 35
Page: 1-13
PDF size: 451.89 Kb.


ABSTRACT

Introduction: Idiopathic inflammatory myopathies constitute a group of muscle diseases characterized by chronic muscle weakness and muscle inflammation of unknown etiology.
Objective: To identify the clinical and immunological characteristics and organ damage in patients with idiopathic inflammatory myopathies.
Method: An observational, descriptive, cross-sectional study was carried out in 52 patients with diagnosis of idiopathic inflammatory myopathy, followed up in the protocolized service of Rheumatology at Hermanos Ameijeiras Clinical Surgical Hospital from January 2016 to January 2017. The qualitative variables were calculated with the percentages in each group. Pearson's Chi-square (Fisher's exact statistic) (95% significance level (α = 0.05) was used to relate the presence of antibodies and the type of myopathy as well as the presence of clinical manifestations of idiopathic inflammatory myopathies.
Results: 80.8% were women of the total patients studied, 61.5% non-white skin color, 86.5% of urban origin. The mean age at the beginning was 42.8 ± 13.2 years, time delay to diagnosis was 8.8 ± 7.0 months, mean time of evolution of the disease of 7.5 ± 7.1 years. 80.8% were in remission, 50% had specific antibodies. Hypertension was found in 28.8% of the patients and 23.1% had interstitial pneumonia. Arthritis was present in 96.2%. We found 26.9% had specific Jo1 antibodies and 21.2% Ro 52.
Conclusions: Urban origin female patients predominated, in their fourth decade of life, the more frequent specific antibodies found was anti Jo-1, which was associated with the presence of interstitial lung disease.


REFERENCES

  1. Bohan A, Peter JB. Polymyositis and dermatomyositis. Engl J Med. 1975;292:344-77.

  2. Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann RheumDis. 2017 [acceso: 02/01/2020];76(12):1955-64. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5736307/

  3. Tsaltskan V, Aldous A, Serafi S, Yakovleva A, Sami H, Mamyrova G, et al. Long-term outcomes in juvenile myositis patients. Semin Arthritis Rheum. 2020;50(1):149-55. https://doi.org/10.1016/j.semarthrit.2019.06.014

  4. Svensson J, Arkema EV, Lundberg IE, Holmqvist M. Incidence and prevalence of idiopathic inflammatory myopathies in sweden: a nationwide population-based study. Rheumatology (Oxford). 2017;56(5):802-10. https://doi.org/10.1093/rheumatology/kew503

  5. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. CurrOpin Neurol. 2016[acceso: 02/01/2020];29(5):662-73. Disponible en: Disponible en: https://journals.lww.com/coneurology/Abstract/2016/10000/Advances_in_serological_diagnostics_of.18.aspx

  6. Lundberg IE, Tjärnlund A, Bottai M. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann of Rheum Dis, 2018[acceso: 02/01/2020];76:1955-64. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846474/

  7. Bottai M, Tjärnlund A, Santoni G. International Myositis Classification Criteria Project consortiumthe Euromyositis register and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). inflammatory myopathies and their major subgroups: a methodology report. RMD Open. 2017[acceso: 02/01/2020];3(2). Disponible en. Disponible en. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846474/

  8. Zamarrón de Lucas E, Carrera LG, Bonilla G, Petit D. Síndrome antisintetasa: análisis de 11 casos. MedClínic. 2017;148(4):166-69. https://doi.org/10.1016/j.medcli.2016.11.021

  9. McHugh NJ, Tansley SL. Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14(5):290-302. https://doi.org/10.1038/nrrheum.2018.56

  10. Tieu J, Lundberg I, Limaye V. Idiopathic inflammatory myositis. Best Practice&Research. Clin Rheumatol. 2016;30(1):149-68 https://doi.org/10.1016/j.berh.2016.04.007

  11. Oldroyd A, Lilleker J, Chinoy H. Idiopathic inflammatory myopathies -a guide to subtypes, diagnostic approach and treatment. Clin Med (Lond). 2017[acceso: 02/01/2020];17(4):322-28. Disponible en: Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297649/

  12. Suzuki S. Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology. Autoimmun Rev. 2017[acceso: 02/01/2020];16(7):693-700. Disponible en: Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S1568997217301234?via%3Dihub

  13. Mira-Bleda E, García-Pérez B, García-Ortega AA, Salazar Rosa V. Miositis necrotizante autoinmune y dermatomiositis por estatinas: un diagnóstico diferencial complejo. Rev Esp Casos Clin Med Intern (RECCMI). 2019. https://doi.org/10.32818/reccmi.a4n2a7

  14. Bevilacqua JA, Earle N. Miopatías inflamatorias. Rev. Med. Clin. Condes. 2018[acceso: 02/01/2020];29(6):611-21. Disponible en Disponible en http://www.pri.sld.cu/wp-content/uploads/2020/09/MIOPATIAS.pdf

  15. Aussy A, Boyer O, Cordel N. Dermatomyositis and Immune-mediated necrotizing myopathies: a window on autoimmunity and cancer. Front Immunol. 2017[acceso: 02/01/2020];8:992. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/28871260/

  16. Sato S, Kuwana M, Hirakata M. Clinical characteristics of Japanese patients with anti OJ (anti isoleucyltRNAsynthetase) autoantibodies. Rheumatology (Oxford) 2007[acceso: 02/01/2020];46(5):842-5. Disponible en: Disponible en: https://academic.oup.com/rheumatology/article/46/5/842/2289414

  17. Shamim E, Rider L, Pandey J. Differences in Idiopathic Inflammatory Myopathy phenotypes and genotypes between meso American mestizos and north American caucasians. Arthritis & Rheumatism. 2002[acceso: 02/01/2020];46(7):1885-93. Disponible en: Disponible en: http://myonet.eu/wp-content/uploads/2013/05/15.-Shamim-et-al.-2002.pdf

  18. Mustafa KN, Dahbour SS. Clinical characteristics and outcomes of patients with idiopatic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol. 2010[acceso: 02/01/2020];29(12):1381-5. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/20407818/

  19. O'Hanlon TP, Miller FW. Genetic risk andprotective factors for the idiopathic inflammatory myopathies. Current Rheumatology Reports. 2009. https://doi.org/10.1007/s11926-009-0040-2

  20. Gómez GN, Gargiulo Mde L, Pérez N, Collado MV, Suárez LV, Khoury M, et al. Autoantibodies in adult patients with idiopathic inflammatory myopathies in Buenos Aires. Medicina (B Aires). 2016[acceso: 02/01/2020];76(3):129-34. Disponible en: Disponible en: https://core.ac.uk/reader/196712494?utm_source=linkout

  21. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculo skeletal Disorders. 2012;13:103-4. https://doi.org/10.1186/1471-2474-13-103

  22. Smoyer-Tomic KE, Amato AA, Fernandes AW. Incidence and prevalence of idiopathic inflammatory myopathies among commercially insured, Medicare supplemental insured, and Medicaid enrolled populations: an administrative claims analysis. BMC Musculo skeletal Disorders . 2012;13:103-4. https://doi.org/10.1186/1471-2474-13-103

  23. Campo Voegeli A. Dermatomiositis y sistema del complemento: relación entre actividad de la enfermedad y grado de activación del complemento. Comparación con marcadores bioquímicos tradicionales. Tesis para la obtención del título de Doctor en Medicina. Universidad de Barcelona. Barcelona, España. 2013.

  24. Kalluru R, Hart H, Corkill M, Ng KP. Long-term follow-up of patients with idiopathic inflammatory myopathy at Waitemata District Health Board. NZMJ. 2016[acceso: 02/01/2020];129(1429):50-6. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/26914299/

  25. Maraví TZ, Burgos PI, Prieto-González S. Manifestaciones clínicas y anticuerpos asociados y específicos de miositis en 15 pacientes chilenos con dermatomiositis: serie clínica en un centro universitario. Rev. méd. Chile. 2020[acceso: 02/01/2020];148(2). Disponible en: Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000200160

  26. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012[acceso: 02/01/2020];14:275-85. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/22410829/

  27. Nuño L, Joven B, Carreira P, Maldonado V, Larena C, Llorente I, et al. Registro de pacientes con miopatía Inflamatoria de la Sociedad Madrileña de Reumatología: análisis descriptivo Reumatol Clin. 2017;13(6):331-7l. https://doi.org/10.1016/j.reuma.2016.07.010

  28. Hochbert MC, Feldman D, Stevens MB. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum. 1990;20:114-20.

  29. Xicará Sarpeque WE. Caracterización clínica de las miopatías inflamatorias. Tesis para optar por el grado de maestro en Ciencias con especialidad en Reumatología. Universidad de San Carlos de Guatemala. Guatemala, Guatemala. 2014.

  30. Torres C, Belmonte R, Carmona L. Survival, mortality and cuse of death in inflammatory myopathies. Autoimmunity. 2008[acceso: 02/01/2020];39:205-15. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/16769654/

  31. Lega JC, Fabien N, Reynaud Q. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev. 2014[acceso: 02/01/2020];13:883-91. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/24704867/

  32. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Szollosi L, Danko K. Four dermatomyositis-specific autoantibodies- TIF1gamma, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014[acceso: 02/01/2020];13:1211-9. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/25182203/

  33. O’Callaghan A, Labrador-Horrillo M, Solans-Laque R. Myositis-specific and myositis-associated antibodies in a series of eighty-eight mediterranean patients with Idiopathic Inflammatory Myopathy. Arthritis & Rheumatism. 2006[acceso: 02/01/2020];55(5):791-8. Disponible en: Disponible en: https://pubmed.ncbi.nlm.nih.gov/17013837/

  34. 34 Ernste FC, Reed AM. Idiopathic inflammatory myopathies: current trends in pathogenesis, clinical features, and up-to-date treatment recommendations. Mayo Clin Proc. 2013. https://doi.org/10.1016/j.mayocp.2012.10.017/

  35. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011;38(10):973-9. https://doi.org/10.1111/j.1346-8138.2011.01262.x/




2020     |     www.medigraphic.com